New weekly shot could help control blood sugar in type 2 diabetes

NCT ID NCT07163624

Completed Disease control Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new once-weekly injection called UBT251 in 211 adults with type 2 diabetes. Participants received either UBT251, a placebo, or the existing drug semaglutide for 24 weeks. The main goal was to see how well UBT251 lowers blood sugar (HbA1c) and to find the right dose for future larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UBT251 injection (a once-weekly drug for type 2 diabetes)
What this could lead to: If successful, this could provide a new once-weekly treatment option for people with type 2 diabetes, potentially improving blood sugar control.
What could go wrong: This is a Phase 2 trial with only 211 participants, so results may not apply to everyone. The drug may not work better than existing treatments like semaglutide, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

The United Bio-Technology (Hengqin) Co., Ltd.

Zhuhai, Guangdong, 519000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.